^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    177Lu-PSMA-R2

    i
    Other names: 177Lu-PSMA-R2, Lu177-PSMA-R2, lutetium-177 PSMA-R2, 177Lu-PSMA-SR6, AAA 602, AAA602, AAA-602
    Associations

    News

    Trials
    Company:
    Novartis
    Drug class:
    Ionizing radiation emitter, PSMA inhibitor
    Related drugs:
    Associations

    News

    Trials
    over3years
    PROter: 177Lu-PSMA-R2 in Patients With PSMA Positive Progressive, Metastatic, Castration Resistant Prostate Cancer (clinicaltrials.gov)
    P1/2, N=96, Recruiting, Advanced Accelerator Applications | Trial completion date: Jun 2022 --> Dec 2022 | Trial primary completion date: Jun 2022 --> Dec 2022
    Clinical • Trial completion date • Trial primary completion date
    |
    CYP17A1 (Cytochrome P450 Family 17 Subfamily A Member 1)
    |
    177Lu-PSMA-R2